ClinicalTrials.gg
RecruitingNCT07164170Updated Jun 17, 2026

A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib

A Phase 2 interventional study of ABSK043 in combination with Glecirasib in Non-Small Cell Lung Cancer, sponsored by Abbisko Therapeutics Co, Ltd. Recruiting at 17 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by Abbisko Therapeutics Co, Ltd (part of Abbisko Cayman Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
86
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China — 763 open to participants now, 987 under way, 203 of them phase 3. Carcinoma, Non-Small-Cell Lung · China.

Planned enrollment
858th of 1,593
86 · median 100
Started
2025
with 207 others
Phase 2
650 of 1,880
273 open now
Primary completion
2028-12
later than 832 of 986 live
Registered
1,619th of 1,880
by date

Among the 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China, this one is the 858th largest by planned enrollment of the 1,593 interventional ones that give a count, is one of 208 that started in 2025, is one of 650 in phase 2, reaches primary completion later than 832 of the 986 other live ones, and was the 1,619th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

763 of the 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China are open now. Recruiting first, the newest first:

758 more — sign in →

All 763 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,880 studies in Carcinoma, Non-Small-Cell Lung with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, open-label phase 2 study that will enroll KRASG12C mutated patients with locally advanced or metastatic NSCLC, receiving treatment (ABSK043 in combination with Glecirasib) in a 21-day combination cycle.

Read the detailed description

The study consists of an escalation part and an expansion part. The escalation part will evaluate the safety, tolerability, preliminary efficacy, and PK profile of different doses of ABSK043 in combination with Glecirasib, and the combination regimen recommended for the expansion part. The expansion part will further evaluate the safety, PK profile, and anti-tumor efficacy of ABSK043 in combination with Glecirasib at the one or more recommended dose (s).

Up to 86 patients with locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) are planned to be enrolled in the study.

  • Escalation Part: up to 50 previously treated patients with KRASG12C mutation.
  • Expansion Part: up to 36 treatment-naïve patients with KRASG12C mutation.
03

Conditions studied

  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Prior to any protocol- specific procedures are performed, the patient should understand and voluntarily sign and date the written form.
  2. Gender was not limited patients aged ≥18 years at the time of signing the informed consent.
  3. or cytologically confirmed locally advanced, unresectable, or non-small cell lung cancer (NSCLC).

    For patients in the dose-escalation cohort (Part A) of the escalation part:

    Patients must have experienced disease progression following at least one line of prior standard systemic therapy, but no more than two .

    For patients in the dose confirmation cohort (Part B) of the escalation part :

    1. Prior treatment requirements for patients in cohort (Part B) are the same as those for patients in (Part A);
    2. Documented or central laboratory test report confirmed that the tumor was expression positive (≥1%) .

    For patients in the expansion cohort of the expansion part :

    1. Patients who have not received prior systemic therapy for locally advanced or unresectable/metastatic disease;
    2. Central laboratory test report confirmed that the tumor was PD-L1 expression positive (≥1%) .
  4. Tumor tissue or blood test report confirmed KRASG12C mutation.
  5. Patients must have at least one as defined by v1.1.
  6. (ECOG) performance status of 0\~1.
  7. Expected survival time of ≥3 months.
  8. Patients must have adequate organ and bone marrow function.

Exclusion criteria

Exclusion Criteria:

  1. Histological or cytological evidence of small cell lung cancer or neuroendocrine carcinoma components.
  2. Toxicities from prior antitumor therapy have not returned to baseline or stabilized.
  3. Patients with active .
  4. The patient currently has active interstitial lung disease.
  5. Patients currently have active disease or a history of autoimmune disease that may be at risk for recurrence.
  6. Any condition requiring systemic treatment with .
  7. Uncontrolled or significant cardiovascular disease.
  8. Has a known (HIV) infection that is not well controlled.
  9. Any evidence of severe or uncontrolled diseases or other factors which in the Investigator's opinion makes it undesirable for the patients to participate in the study
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
86 participants (estimated)

Study arms

  • Experimental
    Experimental: ABSK043 in combination with Glecirasib

    This is an open-label phase 2 study with an escalation part and an expansion part. • Escalation Part: up to 50 previously treated patients with KRASG12C mutation. Does Escalation Cohort(Part A): up to 30previously treated patients with KRASG12C mutation. Dose Confirmation Cohort(Part B): up to 20previously treated patients with KRASG12C mutation. • Expansion Part: up to 36 treatment-naïve patients with KRASG12C mutation.

    Drug: ABSK043 in combination with Glecirasib

Interventions

  • DrugABSK043 in combination with Glecirasib

    Drug pages: PD-L1 Inhibitor ABSK043 · Glecirasib

    Dose escalation cohort( Part A) ABSK043 150 mg BID in combination with Glecirasib 200 mg QD will be selected as the starting dose. Based on the accumulated safety data and PK profile, the Safety Review Committee (SRC), composed of the investigator and the sponsor, may discuss and agree to allow exploration of other possible doses. Dose confirmation cohort (Part B) and Expansion cohort Patients in dose confirmation cohort and expansion cohort will receive the recommended dose in dose escalation cohort and be evaluated for safety and preliminary anti-tumor activity. All patients will continue to receive combination therapy every 21 days until disease progression, death, loss to follow-up, withdrawal of consent, intolerable toxicity, investigator decision to discontinue treatment, or end of the study.

06

What researchers measure

Primary outcomes

  1. Incidence of DLT

    Dose-limiting toxicities

    Time frame: At the end of Cycle 1 (each cycle is 21 days)

  2. AEs

    Adverse events

    Time frame: From the time the patient signs the informed consent form throughout the study and up to 90 days after the last dose of ABSK043 or 30 days after the last dose of Glecirasib, whichever occurs first, up to 30 months.

  3. SAEs

    Serious adverse events (SAEs)

    Time frame: From the time the patient signs the informed consent form throughout the study and up to 90 days after the last dose of ABSK043 or 30 days after the last dose of Glecirasib, whichever occurs first, up to 30 months.

  4. AESIs AESIs

    Adverse events of special interest (AESIs)

    Time frame: From the time the patient signs the informed consent form throughout the study and up to 90 days after the last dose of ABSK043 or 30 days after the last dose of Glecirasib, whichever occurs first, up to 30 months.

  5. ORR

    objective response rate

    Time frame: From date of enrolment#Cycle1 Day1# until disease progression, death, loss to follow-up, withdrawal of consent, intolerable toxicity, investigator's decision to discontinue treatment, or end of study, whichever comes first, assessed up to 50 months.

Secondary outcomes

  1. Cmax

    Maximum observed concentration

    Time frame: From the date of enrolment #Cycle1 Day1# to #Cycle7#, and for patients who discontinue treatment before cycle 7 (C7), PK sampling will be performed at the EOT visit and assessed up to 10 months

  2. AUC

    area under the concentration-time curve

    Time frame: From the date of enrolment #Cycle1 Day1# to #Cycle7#, and for patients who discontinue treatment before cycle 7 (C7), PK sampling will be performed at the EOT visit and assessed up to 10 months.

  3. t1/2 t1/2

    elimination half-life

    Time frame: From the date of enrolment #Cycle1 Day1# to #Cycle7#, and for patients who discontinue treatment before cycle 7 (C7), PK sampling will be performed at the EOT visit and assessed up to 10 months.

  4. Vz/F

    apparent volume of distribution

    Time frame: From the date of enrolment #Cycle1 Day1# to #Cycle7#, and for patients who discontinue treatment before cycle 7 (C7), PK sampling will be performed at the EOT visit and assessed up to 10 months.

  5. CL/F

    apparent oral clearance

    Time frame: From the date of enrolment #Cycle1 Day1# to #Cycle7#, and for patients who discontinue treatment before cycle 7 (C7), PK sampling will be performed at the EOT visit and assessed up to 10 months.

  6. Cmax,ss

    maximum observed concentration after multiple doses maximum observed concentration after multiple doses maximum observed concentration after multiple doses

    Time frame: From the date of enrolment #Cycle1 Day1# to #Cycle7#, and for patients who discontinue treatment before cycle 7 (C7), PK sampling will be performed at the EOT visit and assessed up to 10 months.

  7. Cmin,ss

    minimum observed concentration after multiple doses

    Time frame: From the date of enrolment #Cycle1 Day1# to #Cycle7#, and for patients who discontinue treatment before cycle 7 (C7), PK sampling will be performed at the EOT visit and assessed up to 10 months.

  8. AUCtau,ss

    area under the concentration-time curve after multiple doses

    Time frame: From the date of enrolment #Cycle1 Day1# to #Cycle7#, and for patients who discontinue treatment before cycle 7 (C7), PK sampling will be performed at the EOT visit and assessed up to 10 months.

  9. AR

    accumulation ratio

    Time frame: From the date of enrolment #Cycle1 Day1# to #Cycle7#, and for patients who discontinue treatment before cycle 7 (C7), PK sampling will be performed at the EOT visit and assessed up to 10 months.

  10. tmax

    time to maximum observed concentration

    Time frame: From the date of enrolment #Cycle1 Day1# to #Cycle7#, and for patients who discontinue treatment before cycle 7 (C7), PK sampling will be performed at the EOT visit and assessed up to 10 months.

  11. DOR DOR

    Duration of response

    Time frame: From date of enrolment#Cycle1 Day1# until disease progression, death, loss to follow-up, withdrawal of consent, intolerable toxicity, investigator's decision to discontinue treatment, or end of study, whichever comes first, assessed up to 50 months.

  12. PFS

    Progression-free survival

    Time frame: From date of enrolment#Cycle1 Day1# until disease progression, death, loss to follow-up, withdrawal of consent, intolerable toxicity, investigator's decision to discontinue treatment, or end of study, whichever comes first, assessed up to 50 months.

  13. DCR

    Disease control rate

    Time frame: From date of enrolment#Cycle1 Day1# until disease progression, death, loss to follow-up, withdrawal of consent, intolerable toxicity, investigator's decision to discontinue treatment, or end of study, whichever comes first, assessed up to 50 months.

  14. TTP

    Time to progression

    Time frame: From date of enrolment #Cycle1 Day1# until disease progression, assessed up to 50 months.

  15. OS

    Overall survival Overall survival Overall survival

    Time frame: From date of enrolment#Cycle1 Day1# until disease progression, death, loss to follow-up, withdrawal of consent, intolerable toxicity, investigator's decision to discontinue treatment, or end of study, whichever comes first, assessed up to 50 months.

07

Study locations

10 of 17 sites recruiting
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui, China
    Not yet recruiting
    • Yiruo Zhang · Contact
    • Yiruo Zhang · Principal investigator
  • Beijing Cancer Hospital
    Beijing, Beijing Municipality, China
    Recruiting
    • Jian Fang · Contact
    • Jian Fang · Principal investigator
  • Cancer Hospital Chinese Academy of Medical Sciences
    Beijing, Beijing Municipality, China
    Not yet recruiting
    • Jianchun Duan · Contact
    • Jianchun Duan · Principal investigator
  • Fujian Cancer Hospital
    Fuzhou, Fujian, China
    Recruiting
    • Zhangzhou Huang · Contact
    • Zhangzhou Huang · Principal investigator
  • The First Affiliated Hospital of Sun Yat-sen University
    Guangzhou, Guangdong, China
    Recruiting
    • Kejing Tang · Contact
    • Tang Tang · Principal investigator
  • Guangxi Medical University Cancer Hospital & Guangxi Cancer Institude
    Nanning, Guangxi, China
    Not yet recruiting
    • Shaozhang Zhou · Contact
    • Shaozhang Zhou · Principal investigator
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang, China
    Recruiting
    • Lihua Shang · Contact
    • Lihua Shang · Principal investigator
  • Henan Cancer Hospital
    Zhengzhou, Henan, China
    Not yet recruiting
    • Qiming Wang · Contact
    • Qiming Wang · Principal investigator
  • Tongji Hospital Tongji Medical College of Hust
    Wuhan, Hubei, China
    Not yet recruiting
    • Qian Chu · Contact
    • Qian Chu · Principal investigator
  • Hunan Cancer Hospitial
    Changsha, Hunan, China
    Recruiting
    • Yongchang Zhang · Contact
    • Yongchang Zhang · Principal investigator
  • Zhongda Hospital Southeast University
    Nanjing, Jiangsu, China
    Recruiting
    • Shuhua Han · Contact
    • Shuhua Han · Principal investigator
  • The First Hospital of China Medical University
    Shenyang, Liaoning, China
    Recruiting
    • Mingfang Zhao · Contact
    • Mingfang Zhao · Principal investigator
  • Central Hospital Affiliated to Shangdong First Medical University
    Jinan, Shangdong, China
    Not yet recruiting
    • Meili Sun · Contact
    • Meili Sun · Principal investigator
  • Shanghai Chest Hospital
    Shanghai, Shanghai Municipality, China
    Recruiting
    • Shun Lu · Contact
    • Shun Lu · Principal investigator
  • Shanghai Pulmonary Hospital
    Shanghai, Shanghai Municipality, China
    Recruiting
    • Chunxia Su · Contact
    • Chunxia Su · Principal investigator
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi’an, Shanxi, China
    Not yet recruiting
    • Yu Yao · Contact
    • Yu Yao · Principal investigator
  • West China Hospital Sichuan University
    Chengdu, Sichuan, China
    Recruiting
    • Guowei Che · Contact
    • Guowei Che · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Dec 2028, 39 months after the start.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 39 months is close to that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2025
First posted
Sep 10, 2025
StartActual
Sep 22, 2025
Primary completionEst.
Dec 30, 2028
CompletionEst.
Jul 30, 2029
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07164170
Responsible party
Sponsor
First posted
Sep 10, 2025
Start date
Sep 22, 2025
Primary completion
Dec 30, 2028 (estimated)
Completion
Jul 30, 2029 (estimated)
Last update
Jun 17, 2026

Study contacts

Yinan Lin
Contact
clinical@abbisko.cn
+86-21-68910052

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: PD-L1 Inhibitor ABSK043 · Glecirasib

Start the discussion